Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Sham-controlled, Comparative Study of SI-6603 in Subjects With Lumbar Disc Herniation (Phase 3)

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-blind, Sham-controlled, Comparative Study of SI-6603 in Subjects With Lumbar Disc Herniation (Phase 3)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Condoliase (Primary)
  • Indications Intervertebral disc displacement
  • Focus Registrational; Therapeutic Use
  • Acronyms Discovery 6603
  • Sponsors Seikagaku Corporation

    • Most Recent Events

    • 15 Jul 2024 Results presented in the Ferring Pharmaceuticals Media Release.
    • 24 Jun 2024 According to a Ferring Pharmaceuticals Media Release, an evaluation of early treatment response to SI-6603 from the completed United States Phase 3 Discovery 6603 clinical trial , two analyses of data presented at the American Society of Pain and Neuroscience (ASPN) 2024 Annual Meeting, Monday, July 15, 2024, at 8:00 a.m. ET.
    • 08 Apr 2024 According to a Ferring Pharmaceuticals Media Release, data from this study was presented at the American Society of Interventional Pain Physicians (ASIPP) Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top